An observational study to validate the Satisfaction Measure of the Injection of Growth Hormone Therapy (SMIGHTy) questionnaire.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this phase 4 clinical trial publication.

The objective of this study was to psychometrically evaluate a tool to measure adult caregivers' level of satisfaction with the delivery device used to administer injections of recombinant human growth hormone (rhGH) to a child - the Satisfaction Measure of the Injection of Growth Hormone Therapy (SMIGHTy*) questionnaire.

Why It Was Studied

This study assessed only adult caregivers; the instrument was not validated for use by young or adult patients.

Who Took Part

The age groups tagged for this paper are children, teenagers and adults, both men and women.

One hundred caregivers who administer rhGH to a child using an injection device completed the SMIGHTy questionnaire at baseline and 7-14 days later, and also completed other measures of treatment adherence and treatment satisfaction at baseline.

What Was Measured

This study assessed only adult caregivers; the instrument was not validated for use by young or adult patients.

Topics PubMed links to this paper include Delivery of Health Care, Hormone Replacement Therapy, Human Growth Hormone, Patient Satisfaction and Surveys and Questionnaires.

What This Means in Plain Language

This is a phase 4 clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2011 (Current medical research and opinion), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.